Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumathi Nambiar

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Pharmacoepidemiology and Drug Safety|May 30, 2014
Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare dataMonika Houstoun, Marsha E Reichman, David J Graham, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation InitiativeRachel G Greenberg, Amy Corneli, John Bradley, et al.
Nature Microbiology|April 9, 2025
Author Correction: Combining antibiotics to tackle antimicrobial resistanceWilliam Hope, Sumathi Nambiar, Seamus O'Brien, et al.
Nature Microbiology|March 27, 2025
Combining antibiotics to tackle antimicrobial resistanceWilliam Hope, Sumathi Nambiar, Seamus O'Brien, et al.
Open Forum Infectious Diseases|June 24, 2026
Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure InfectionsJessica Howard-Anderson, Toshimitsu Hamasaki, Lizhao Ge, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2023
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2022
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical TrialsJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2021
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal DrugsElizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2023
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical NeedYuliya Yasinskaya, Shukal Bala, Ursula Waack, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2023
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug DevelopmentCaroline J Jjingo, Shukal Bala, Ursula Waack, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Pharmacoepidemiology and Drug Safety|May 30, 2014
Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare dataMonika Houstoun, Marsha E Reichman, David J Graham, et al.
Contemporary Clinical Trials Communications|April 27, 2018
Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation InitiativeRachel G Greenberg, Amy Corneli, John Bradley, et al.
Nature Microbiology|April 9, 2025
Author Correction: Combining antibiotics to tackle antimicrobial resistanceWilliam Hope, Sumathi Nambiar, Seamus O'Brien, et al.
Nature Microbiology|March 27, 2025
Combining antibiotics to tackle antimicrobial resistanceWilliam Hope, Sumathi Nambiar, Seamus O'Brien, et al.
Open Forum Infectious Diseases|June 24, 2026
Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure InfectionsJessica Howard-Anderson, Toshimitsu Hamasaki, Lizhao Ge, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2023
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2022
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical TrialsJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2021
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal DrugsElizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2023
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical NeedYuliya Yasinskaya, Shukal Bala, Ursula Waack, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2023
Food and Drug Administration Public Workshop Summary-Addressing Challenges in Inhaled Antifungal Drug DevelopmentCaroline J Jjingo, Shukal Bala, Ursula Waack, et al.
Pageof 5